Steven Cohen's ACAD Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.49 M shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $31.72 M, representing 0.05% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 40 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in ACAD, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 2.93 M shares. Largest reduction occurred in Q3 2024, reducing 3.71 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +1.08 M | Add 0.00% | 1.08 M | $22.59 |
| Q3 2014 | -157,000 | Reduce 14.51% | 925,000 | $24.76 |
| Q4 2014 | +93,600 | Add 10.12% | 1.02 M | $31.75 |
| Q1 2015 | +1.23 M | Add 120.63% | 2.25 M | $32.59 |
| Q2 2015 | -900,044 | Reduce 40.05% | 1.35 M | $41.88 |
| Q3 2015 | +664,744 | Add 49.34% | 2.01 M | $33.07 |
| Q4 2015 | -1.71 M | Reduce 84.90% | 303,800 | $35.65 |
| Q1 2016 | +1.92 M | Add 631.63% | 2.22 M | $27.96 |
| Q2 2016 | -1.02 M | Reduce 46.03% | 1.2 M | $32.46 |
| Q3 2016 | +871,800 | Add 72.67% | 2.07 M | $31.81 |
| Q4 2016 | -846,500 | Reduce 40.86% | 1.22 M | $28.84 |
| Q1 2017 | +706,200 | Add 57.65% | 1.93 M | $34.38 |
| Q2 2017 | -525,178 | Reduce 27.19% | 1.41 M | $27.89 |
| Q3 2017 | -680,822 | Reduce 48.42% | 725,200 | $37.67 |
| Q4 2017 | +1.67 M | Add 230.41% | 2.4 M | $30.11 |
| Q1 2018 | +1.96 M | Add 81.86% | 4.36 M | $22.47 |
| Q2 2018 | -1.26 M | Reduce 28.98% | 3.09 M | $15.27 |
| Q3 2018 | -1.29 M | Reduce 41.61% | 1.81 M | $20.76 |
| Q4 2018 | +439,600 | Add 24.33% | 2.25 M | $16.17 |
| Q1 2019 | -1.86 M | Reduce 82.57% | 391,528 | $26.85 |
| Q2 2019 | -389,928 | Reduce 99.59% | 1,600 | $26.88 |
| Q3 2019 | -1,600 | Sold Out | 0 | $0.00 |
| Q4 2019 | +671,009 | New Buy | 671,009 | $42.78 |
| Q1 2020 | -671,009 | Sold Out | 0 | $0.00 |
| Q2 2020 | +198,510 | New Buy | 198,510 | $48.47 |
| Q3 2020 | +379,685 | Add 191.27% | 578,195 | $41.25 |
| Q4 2020 | -411,095 | Reduce 71.10% | 167,100 | $53.46 |
| Q1 2021 | -167,100 | Sold Out | 0 | $0.00 |
| Q4 2022 | +1.12 M | New Buy | 1.12 M | $15.92 |
| Q1 2023 | -456,394 | Reduce 40.90% | 659,506 | $18.82 |
| Q2 2023 | +232,420 | Add 35.24% | 891,926 | $23.95 |
| Q3 2023 | -841,283 | Reduce 94.32% | 50,643 | $20.84 |
| Q4 2023 | +342,184 | Add 675.68% | 392,827 | $31.31 |
| Q1 2024 | +383,873 | Add 97.72% | 776,700 | $18.49 |
| Q2 2024 | +2.93 M | Add 377.68% | 3.71 M | $16.25 |
| Q3 2024 | -3.71 M | Sold Out | 0 | $0.00 |
| Q4 2024 | +2.23 M | New Buy | 2.23 M | $18.35 |
| Q1 2025 | +2.42 M | Add 108.35% | 4.65 M | $16.61 |
| Q2 2025 | -1.48 M | Reduce 31.74% | 3.17 M | $21.57 |
| Q3 2025 | -1.69 M | Reduce 53.15% | 1.49 M | $21.34 |
Steven Cohen's ACADIA Pharmaceuticals Investment FAQs
Steven Cohen first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q2 2014, acquiring 1,082,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held ACADIA Pharmaceuticals Inc. (ACAD) for 40 quarters since Q2 2014.
Steven Cohen's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q2 2024, adding 3,710,140 shares worth $60.29 M.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,486,357 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $31.72 M.
As of the Q3 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.05% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 4,647,816 shares, as reported at the end of Q1 2025.